Prostate cancer is costly for Californians, according to UCSF researchers

May 29, 2002

Prostate cancer, which largely afflicts older men, is costly for Californians, accounting for more than $180 million in direct health care costs in 1998 and an additional $180 million in lost productivity resulting from premature death. Costs are likely to increase as life expectancy increases, according to UCSF researchers.

"Because prostate cancer is costly and common, it is critical to identify cost-effective screening that will permit early detection," said Wendy Max, PhD, co-director of the UCSF Institute for Health & Aging and professor of health economics, in a study that appears in the June 1, 2002 issue of Cancer.

The researchers noted that California hospitalization costs account for almost three-fifths of the total direct costs, with Medicare and private health insurance sharing almost equally in paying for hospital care. The mean cost for a person hospitalized for prostate cancer was $6,939. In addition, prostate cancer adds an average of $3,388 in costs for a patient hospitalized for another reason, such as heart disease or respiratory illness.

Other costs included emergency department visits, outpatient visits, office-based provider visits, prescription medications, home health care, nursing home care, and losses of productivity for those who died prematurely.

This cancer in Californians follows national patterns, according to the investigators. Prostate cancer is the leading cause of cancer incidence among California men, accounting for 30.4 percent of all cancer cases. A steep increase in annual incidence rates occurred between 1988-1992 with the introduction of screening for prostate specific antigen (PSA), which permitted diagnosis at earlier stages. Deaths due to prostate cancer ranked second to lung cancer and account for 12.2 percent of all cancer deaths in the California, they said.

"Although the number of deaths and new incident cases has declined recently, prostate cancer remains the most common malignancy among white, black, Hispanic, Filipino, Japanese, Chinese, and Asian Indian males," said Max.

She explained that the single greatest risk factor for prostate cancer is age. Prostate cancer incidence is 80 times higher in males age 85 and older compared with men age 40-45 years. The death rate for prostate cancer is 17.7 per 100,000 men for all ages. For men 75-84 years, the death rate was 248 per 100,000 men. For men 85 and older, the death rate more than doubled to 591 per 100,000 men. Other risk factors include positive family history, black racial identity, animal fat consumption, and specific genetic variations.

This study estimated both direct and indirect costs of prostate cancer in California for 1998. Researchers analyzed California specific hospitalization and mortality data. Direct costs were categorized according to the setting in which the cost was incurred. For example, if a patient received radiation treatment as an inpatient, then it was considered a hospitalization cost. If the treatment was received in an outpatient clinic, it was considered an outpatient cost. All hospital discharges with a primary or secondary diagnosis of prostate cancer were included in this study.

Currently, there are conflicting recommendations regarding PSA testing among men without symptoms. The American Urological Association, Inc. and the American Cancer Society (ACS) propose annual PSA testing among asymptomatic men beginning at age 50. The US Preventive Services Task Force and the National Cancer Institute recommend against PSA testing among men with no symptoms.

It has been estimated that the ACS recommendations would cost an estimated $12.7 billion each year and would have profound morbidity consequences and uncertain benefits regarding mortality, said the researchers. That is, many men would be diagnosed with prostate cancer, but many of these men would not die of the disease. Thus, it is necessary to determine who should be screened and when in order to design cost-effective screening protocols. Studies such as this one identify the costs of the disease and are necessary to perform such analyses.
Co-investigators on this study include: Dorothy P. Rice, Sc.D. (Hon.), professor emerita in the UCSF Institute for Health and Aging; Hai-Yen Sung, PhD, research specialist; in the UCSF Institute of Health and Aging; Martha Michel, MPH, UCSF graduate student in bioinformatics; Wendy Breuer, RN, clinical nurse specialist in the UCSF Institute for Health and Aging; and Xiulan Zhang, PhD, former researcher specialist in the UCSF Institute for Health and Aging. This research was funded by state of California Department of Health Services, Cancer Research Program.

University of California - San Francisco

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to